Added to YB: 2026-09-28
Pitch date: 2026-09-23
STLN [bullish]
Starling Oncology, Inc.
-0.89%
current return
Author Info
Banyan Lane Capital aims to present actionable investment research on asymmetric opportunities that, in many cases, are not front and center for investors. Sign up for the newsletter.
Company Info
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States.
Market Cap
$695.1M
Pitch Price
$6.72
Price Target
N/A
Dividend
N/A
EV/EBITDA
-83.87
P/E
-22.42
EV/Sales
1.29
Sector
Health Care Providers and Services
Category
growth
$STLN
STLN (quick overview): The underappreciated story is that 75% of gross profit comes from a stable specialty-pharma business, while the still-new Nexus launch could open large, high-margin profit pools within existing catchment areas. Winning a contract in a new state could make the opportunity wedges start to resemble an exponential curve, though Nexus remains new and not yet fully understood.
Read full article (1 min)